SCHEMBL3594419

SCHEMBL3594419

N#C/C=C/c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.45
JAK3 P52333 1/20 0.45
KDM4E B2RXH2 1/20 0.37
ENPP2 Q13822 1/20 0.37
AHR P35869 1/20 0.36
PTGS1 P23219 1/20 0.36
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
GSK3B P49841 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
CES2 O00748 1/20 0.34
FDPS P14324 1/20 0.33
NFE2L2 Q16236 1/20 0.33
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
FBP1 P09467 1/20 0.32
NQO2 P16083 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594422 1.00 RPS6KA3 (0.45) RPS6KA3JAK3KDM4EENPP2AHR
SCHEMBL20569493 0.87 RPS6KA3 (0.40) RPS6KA3JAK3KDM4EENPP2AHR
SCHEMBL1722537 0.81 NFE2L2 (0.56) KDM4EENPP2NFE2L2FBP1
SCHEMBL1722536 0.81 NFE2L2 (0.56) KDM4EENPP2NFE2L2FBP1
SCHEMBL3916130 0.81 FBP1 (0.39) RPS6KA3JAK3NFE2L2FBP1KIF11
SCHEMBL3916132 0.81 FBP1 (0.39) RPS6KA3JAK3NFE2L2FBP1KIF11
SCHEMBL4728563 0.79 CYP1A2 (0.50) KDM4EAHRPTGS1CCNB2CDK1
SCHEMBL9823840 0.79 CYP1A2 (0.50) KDM4EAHRPTGS1CCNB2CDK1
SCHEMBL3717940 0.79 RPS6KA3 (0.41) RPS6KA3JAK3AHRPTGS1CES2
SCHEMBL5778085 0.78 RPS6KA3 (0.47) RPS6KA3JAK3AHRPTGS1CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087432-A1 PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY NOVARTIS AG (CH) 2010-04-08 US disclosed
EP-1828172-B1 PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY NOVARTIS AG (CH) 2009-11-25 EP disclosed
US-7102046-B2 By reaction of haloaromatics or arylsulfonates with olefins in presence of palladium catalyst, bulky nitrogen base and salt BAYER AKTIENGESELLSCHAFT (DE) 2006-09-05 US disclosed
US-20030105353-A1 Process for the arylation of olefins LANXESS DEUTSCHLAND GMBH (DE) 2003-06-05 US disclosed
EP-1214322-A2 AMINO-TRIAZOLOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-19 EP disclosed
US-6355653-B1 DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS HOFFMANN-LA ROCHE INC. 2002-03-12 US disclosed
WO-2001017999-A2 AMINO-TRIAZOLOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087432-A1 PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY PRLHR, AVPR2, CRHR2 RPS6KA3 384/4885JAK3 2238/4885KDM4E 2754/4885
US-20030105353-A1 Process for the arylation of olefins NEK6, JUN, AOC2 RPS6KA3 1573/4885JAK3 1461/4885KDM4E 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.